Haemophilus b conjugate vaccine (tetanus toxoid conjugate) - Biologic Drug Details

Summary for haemophilus b conjugate vaccine (tetanus toxoid conjugate)

Tradenames:	2
High Confidence Patents:	0
Applicants:	2
BLAs:	2
Suppliers: see list	2
Recent Clinical Trials:	See clinical trials for haemophilus b conjugate vaccine (tetanus toxoid conjugate)

Recent Clinical Trials for haemophilus b conjugate vaccine (tetanus toxoid conjugate)

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1

See all haemophilus b conjugate vaccine (tetanus toxoid conjugate) clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for haemophilus b conjugate vaccine (tetanus toxoid conjugate) Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for haemophilus b conjugate vaccine (tetanus toxoid conjugate) Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Glaxosmithkline Biologicals	HIBERIX	haemophilus b conjugate vaccine (tetanus toxoid conjugate)	Injection	125347		2026-01-13	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for haemophilus b conjugate vaccine (tetanus toxoid conjugate) Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source

International Patents for haemophilus b conjugate vaccine (tetanus toxoid conjugate)

Country	Patent Number	Estimated Expiration
Austria	E463261
Austria	E512670
Australia	2005237289
Australia	2006205656

Last updated: February 13, 2026

What Are the Current Market Dynamics for the Haemophilus B Conjugate Vaccine?

The haemophilus b conjugate vaccine (Hib), specifically the tetanus toxoid conjugate, holds a significant position within the pediatric immunization landscape. The vaccine's demand is driven primarily by reductions in Hib disease burden and global immunization policies.

Market Size and Growth:
Global Hib vaccine market was valued at approximately $2.3 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 8-10% through 2027, reaching roughly $3.4 billion. Growth is supported by increasing vaccination coverage, especially in low- and middle-income countries (LMICs), and rising awareness of Hib-related diseases.

Geographic Distribution:
High-income countries predominantly use combination vaccines that include Hib, decreasing standalone Hib vaccine sales. Conversely, LMICs rely on Gavi-supported programs, which promote Hib vaccine adoption primarily through WHO prequalification and UNICEF procurement. Africa, Southeast Asia, and parts of Latin America are expanding vaccination programs, representing the fastest growth regions.

Market Drivers and Barriers:
Driving factors:

• WHO immunization guidelines recommend Hib inclusion in all infant immunization schedules.
• Government initiatives aim to eliminate Hib disease.
• Technological advances in conjugate vaccine manufacturing, reducing costs.

Barriers include:

• Vaccine hesitancy in some regions.
• Competition from combination vaccines that may reduce standalone Hib demand.
• Price sensitivities in LMICs, affecting procurement decisions.

Competitive Landscape:
Major manufacturers include Sanofi Pasteur, GlaxoSmithKline (GSK), and Serum Institute of India. These companies produce various Hib conjugate formulations (tetanus toxoid, PRP-OMP, PRP-T). Serum Institute's lower-cost formulations dominate LMIC markets, while Western firms focus on combination vaccines for high-income markets.

What Is the Financial Trajectory for the Hemophilus B Conjugate Vaccine?

Revenue Trends:
Sanofi Pasteur's Hiberix and GSK's ActHIB have sustained revenues of approximately $150 million annually each in mature markets. Serum Institute's Hib vaccines account for a significant share of its pediatric vaccine revenues, which total about $1.2 billion annually.

Growth Projections:
Revenue growth prospects are tied to vaccination coverage increases in LMICs. In particular, the Gavi immunization programs projected to distribute over 100 million doses annually by 2025. The expansion into new markets and inclusion in routine immunization schedules can boost revenues by up to 50% over the next five years.

Pricing Dynamics:

• High-income country prices: $15–$25 per dose.
• LMIC prices: $0.20–$1 per dose, facilitated by pooled procurement and tiered pricing models.
• Cost reductions driven by technology investments and larger production scales.

Taxonomies of Cost and Investment:

• Development costs: approximately $50–$100 million per vaccine formulation over several years, including R&D, clinical trials, and regulatory filing.
• Manufacturing investments: $50 million+ for establishing or upgrading production facilities.
• Market expansion costs involve regulatory approvals and distribution logistics.

Profitability Outlook:
While mature markets face stagnant revenues due to established market share, emerging markets offer higher growth potential. The global trend towards universal immunization and reduction of Hib disease burden secures the segment’s long-term profitability.

How Are Market Forces Shaping Future Industry Trends?

Technology and Product Development:
Next-generation conjugate vaccines aim for broader serotype coverage and easier administration. Investments in thermostable formulations aim to improve cold chain logistics, especially for LMIC deployment.

Policy and Funding Influence:
WHO and Gavi decisions significantly impact market volumes. As WHO emphasizes Hib elimination goals, manufacturers aligning product formulations with WHO recommendations stand to gain increased procurement.

Competitive Strategies:
Firms are progressing towards combination vaccines to replace standalone Hib formulations, which could affect standalone vaccine revenues. For example, the 13-valent pneumococcal conjugate vaccine now includes Hib components in some formulations.

Regulatory Environment:
Accelerated approval pathways, particularly in emergent markets, reduce time-to-market, offering earlier revenue streams. However, stringent global standards necessitate extensive clinical data, elevating development costs.

Key Takeaways

• The global Hib vaccine market is expanding, with a compounded annual growth rate of 8-10% forecasted through 2027.
• Market growth is driven by increasing immunization coverage in LMICs, supported by Gavi and WHO initiatives.
• Revenues are concentrated among a few key players, with Serum Institute leading in low-cost formulations.
• Development and manufacturing costs remain high, but economies of scale in LMIC markets offset these expenses.
• The transition toward combination vaccines and novel formulations shapes industry competitiveness and product pipelines.

FAQs

1. What factors most influence Hib vaccine adoption in LMICs?
Funding from Gavi, WHO immunization policies, vaccine affordability, cold chain infrastructure, and public health priorities.

2. How do combination vaccines impact standalone Hib vaccine sales?
Combination vaccines often replace standalone formulations in pediatric schedules, reducing standalone Hib vaccine demand in high-income markets but supporting broader coverage.

3. What are the primary technological advances in Hib vaccines?
Thermostable formulations, expanded serotype coverage, and more immunogenic conjugate carriers.

4. Who are the leading manufacturers of Hib conjugate vaccines?
Sanofi Pasteur, GSK, and Serum Institute of India.

5. What are the major regulatory considerations for Hib vaccines?
Prequalification by WHO, approval from national regulatory agencies, and adherence to Good Manufacturing Practices and safety standards.

---

Sources
[1] Market research reports, 2022-2023.
[2] WHO Immunization Data, 2022.
[3] Gavi Vaccine Investment Strategy, 2022.
[4] Industry financial disclosures and annual reports.